Literature DB >> 30395716

Hepatocellular carcinoma surgical therapy: perspectives on the current limits to resection.

Akhil Chawla1, Cristina Ferrone2.   

Abstract

Hepatocellular carcinoma (HCC) patients often present with late stage disease, which removes surgical resection from the therapeutic treatment options. Only patients with very early disease are recommended for a potentially curative surgical resection. These guidelines have been broadly challenged due to the lack of evidence supporting the use of local therapies over surgery for resectable disease. This review highlights the role of surgical resection for HCC by disease stage, and reports data that supports treatment outside of the accepted Barcelona Clinic Liver Cancer (BCLC) treatment algorithm. As such, the role for surgery in advanced disease is also reviewed. We also highlight the limitations of surgical resection for HCC. With the available data, it is crucial that an update of the current clinical guidelines be introduced, as the current guidelines prohibit the benefit of surgical resection to patients who may be able to achieve a survival benefit.

Entities:  

Keywords:  Liver cancer; cancer treatment; liver resection

Mesh:

Year:  2018        PMID: 30395716     DOI: 10.21037/cco.2018.08.12

Source DB:  PubMed          Journal:  Chin Clin Oncol        ISSN: 2304-3865


  13 in total

1.  Current trends in vena cava reconstructive techniques with major liver resection: a systematic review.

Authors:  Maria Baimas-George; Christoph Tschuor; Michael Watson; Jesse Sulzer; Patrick Salibi; David Iannitti; John B Martinie; Erin Baker; Pierre-Alain Clavien; Dionisios Vrochides
Journal:  Langenbecks Arch Surg       Date:  2020-09-26       Impact factor: 3.445

2.  Gadoxetic acid-enhanced MRI radiomics signature: prediction of clinical outcome in hepatocellular carcinoma after surgical resection.

Authors:  Zhen Zhang; Jie Chen; Hanyu Jiang; Yi Wei; Xin Zhang; Likun Cao; Ting Duan; Zheng Ye; Shan Yao; Xuelin Pan; Bin Song
Journal:  Ann Transl Med       Date:  2020-07

3.  Downstaging of Recurrent Advanced Hepatocellular Carcinoma After Lenvatinib Treatment: Opportunities or Pitfalls? A Case Report.

Authors:  Zhaobo Liu; Zhi Fu; Guangming Li; Dongdong Lin
Journal:  Onco Targets Ther       Date:  2020-10-13       Impact factor: 4.147

4.  Propofol activates AMPK to inhibit the growth of HepG2 cells in vitro and hepatocarcinogenesis in xenograft mouse tumor models by inducing autophagy.

Authors:  Yixiong Wang; Baozhu Xu; Jianying Zhou; Xianyan Wu
Journal:  J Gastrointest Oncol       Date:  2020-12

5.  MicroRNA-548b inhibits proliferation and invasion of hepatocellular carcinoma cells by directly targeting specificity protein 1.

Authors:  Haile Qiu; Gehong Zhang; Bin Song; Junmei Jia
Journal:  Exp Ther Med       Date:  2019-07-25       Impact factor: 2.751

6.  Alarmin augments the antitumor immunity of lentiviral vaccine in ectopic, orthotopic and autochthonous hepatocellular carcinoma mice.

Authors:  Zhili Liu; Zhen Lu; Renwei Jing; Bingfeng Zuo; Xianjun Gao; Gang Han; Han Qi; Li Wu; Yunde Liu; Haifang Yin
Journal:  Theranostics       Date:  2019-05-31       Impact factor: 11.556

7.  Suppression of Hepatocellular Carcinoma Progression through FOXM1 and EMT Inhibition via Hydroxygenkwanin-Induced miR-320a Expression.

Authors:  Li-Fang Chou; Chi-Yuan Chen; Wan-Hua Yang; Chin-Chuan Chen; Junn-Liang Chang; Yann-Lii Leu; Miaw-Jene Liou; Tong-Hong Wang
Journal:  Biomolecules       Date:  2019-12-21

8.  Development and validation of a prognostic and immunotherapeutically relevant model in hepatocellular carcinoma.

Authors:  Yu Wang; Yanting Xie; Junyong Ma; Yizhou Wang; Renyan Gong
Journal:  Ann Transl Med       Date:  2020-09

9.  Hepatocellular Carcinoma Showing Pathological Complete Response to Lenvatinib Monotherapy.

Authors:  Hiroshi Shintani; Shoji Oura; Shinichiro Makimoto
Journal:  Case Rep Oncol       Date:  2021-06-04

Review 10.  Surveillance and Monitoring of Hepatocellular Carcinoma During the COVID-19 Pandemic.

Authors:  Neil Mehta; Neehar Parikh; R Katie Kelley; Bilal Hameed; Amit G Singal
Journal:  Clin Gastroenterol Hepatol       Date:  2020-07-08       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.